Baudax Bio Reports Third Quarter 2020 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/11/2026
- Wall Street ends down as US-Iran peace optimism fades
- S&P 500 EPS growth above 20% is rare. Why 2027 may be at risk
- Goldman Sachs warns AI investment may be crowding out other business spending
- Why Wednesday's inflation print could provide the next dovish catalyst
- Tesla needs Robotaxi flywheel proof to boost investor conviction: Morgan Stanley
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
Baudax Bio (BXRX) Tops Q3 EPS by $1.36
November 9, 2020 7:29 AM ESTBaudax Bio (NASDAQ: BXRX) reported Q3 EPS of $0.62, $1.36 better than the analyst estimate of ($0.74).
The third quarter of 2020 was marked by several important achievements, including continued progress with the commercial launch of ANJESO, the securing of group purchasing agreements with two leading healthcare improvement companies, Vizient and Premier, and the receipt and implementation, on October 1, 2020, of our permanent J-code from the Centers for Medicare and Medicaid Services (CMS), facilitating reimbursement in the hospital outpatient, ambulatory surgery center and physician office settings of care, said Gerri Henwood, President and Chief Executive Officer of... More
